BBNX · Beta Bionics, Inc.

Beta Bionics’ Q1 2026 results reflect accelerating commercial execution and operational leverage: revenue grew 57% YoY to $27.6 million, driven by a 181% surge in PBP channel sales ($10.7M) and continued strength in the DME channel ($16.9M, +22% YoY). Gross margin expanded sharply to 59.5%—an 864-basis-point improvement—indicating favorable channel mix shift toward higher-margin pharmacy-based reimbursement and scaling efficiencies. The company narrowed its net loss to $21.9 million (vs. $28.7M in Q1 2025) and improved Adjusted EBITDA to negative $17.7 million (vs. negative $15.5 million), reflecting disciplined cost management despite increased R&D and commercial investment. Management raised full-year 2026 guidance across all key metrics—revenue ($131–$136M), gross margin (57.5–59.5%), and PBP channel penetration (37–39% of new starts)—signaling confidence in sustained multi-channel momentum. Notably, sequential new patient starts declined modestly (10–20%), yet this was more than offset by higher PBP reimbursement rates and robust single-use product uptake in that channel. Strategically, the initiation of a Phase 2a bihormonal feasibility trial in New Zealand marks a critical inflection point beyond the FDA-cleared iLet platform, expanding the company’s long-term clinical and commercial runway. With $239.5 million in total liquid assets as of March 31, 2026, the company maintains strong financial flexibility to fund ongoing development and commercial expansion without near-term capital needs.